Table 1 Prediction of pCR of HER2-positve breast cancers using HSD17B4 methylation, ER status, and their combination in age groups.
Age | Total | HSD17B4 methylation | ER | Combination marker | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
High | (Positive rate) | Low | Negative | (Negative rate) | Positive | Positive | (Positive rate) | Negative | ||
All | ||||||||||
pCR | 43 | 30 | (69.8%) | 13 | 35 | (81.4%) | 8 | 24 | (55.8%) | 19 |
(pCR rate) | (33.6%) | (75.0%) | (14.8%) | (53.8%) | (12.7%) | (80.0%) | (19.4%) | |||
Non-pCR | 85 | 10 | (11.8%) | 75 | 30 | (35.3%) | 55 | 6 | (7.1%) | 79 |
Total | 128 | 40 | (31.3%) | 88 | 65 | (50.8%) | 63 | 30 | (23.4%) | 98 |
> 55 | ||||||||||
pCR | 28 | 22 | (78.6%) | 6 | 23 | (82.1%) | 5 | 18 | (64.3%) | 10 |
(pCR rate) | (37.8%) | (73.3%) | (13.6%) | (54.8%) | (15.6%) | (78.3%) | (19.6%) | |||
Non-pCR | 46 | 8 | (17.4%) | 38 | 19 | (41.3%) | 27 | 5 | (10.9%) | 41 |
Total | 74 | 30 | (40.5%) | 44 | 42 | (56.8%) | 32 | 23 | (31.1%) | 51 |
45–55 | ||||||||||
pCR | 9 | 5 | (55.6%) | 4 | 6 | (66.7%) | 3 | 3 | (33.3%) | 6 |
(pCR rate) | (33.3%) | (83.3%) | (19.0%) | (46.2%) | (21.4%) | (75.0%) | (26.1%) | |||
Non-pCR | 18 | 1 | (5.6%) | 17 | 7 | (38.9%) | 11 | 1 | (5.6%) | 17 |
Total | 27 | 6 | (22.2%) | 21 | 13 | (48.1%) | 14 | 4 | (14.8%) | 23 |
<45 | ||||||||||
pCR | 6 | 3 | (50.0%) | 3 | 6 | (100.0%) | 0 | 3 | (50.0%) | 3 |
(pCR rate) | (22.2%) | (75.0%) | (13.0%) | (60.0%) | (0.0%) | (100.0%) | (12.5%) | |||
Non-pCR | 21 | 1 | (4.8%) | 20 | 4 | (19.0%) | 17 | 0 | (0.0%) | 21 |
Total | 27 | 4 | (14.8%) | 23 | 10 | (37.0%) | 17 | 3 | (11.1%) | 24 |
